Seaport Startup Snags $1.9 Billion Kidney Deal With Lilly
Eli Lilly has partnered with Boston’s Ascidian to develop RNA exon‑editing therapies for inherited kidney diseases in a deal that could be worth up to $1.9 billion. The collaboration pairs Ascidian’s platform with Lilly’s Seaport genetic‑medicine hub.





























